Clinically, vemurafenib is not currently used for the treatment of non-BRAF mutant melanoma due to a lack of efficacy and the paradoxical transactivation of the key driver of melanomagenesis, the MAPK pathway, and the subsequent cell proliferation [39]. This evidence concerns the gene BRAF and melanoma.